瑞波西汀与文拉法辛治疗脑卒中后抑郁症的疗效比较

Comparention of Efficacy of Reboxetine and Venlanfaxine for Post-stroke Depression Patients

目的:比较瑞波西汀与文拉法辛治疗脑卒中后抑郁症(PSD)的疗效与不良反应。方法:选择2010年4月-2011年11月在我院治疗的127例PSD患者,随机分为两组,分别用瑞波西汀(64例)和文拉法辛(63例)治疗12周。在治疗前以及治疗后6周和12周末采用汉密尔顿抑郁(HAMD)量表、汉密尔顿焦虑(HAMA)量表和神经功能缺损评分(NIHSS)量表评定疗效并记录不良反应。结果:治疗12周后,两组患者HAMD、HAMA以及NIHSS均较治疗前显著降低(P<0.05)。瑞波西汀组总有效率为78.1%,文拉法辛组的总有效率为79.4%,两组比较差异无统计学意义(P>0.05)。两组均未见明显不良反应发生。结论:瑞波西汀与文拉法辛治疗PSD效果相当,安全性均较好。

OBJECTIVE： To compare the clinical efficacy and safety of reboxetine and venlanfaxine for post-stroke depression （PSD） patients. METHODS： 127 PSD patients in our hospital from 2010 Apr. to 2011 Dec. were randomly divided into 2 groups. They were treated with reboxetine （n=64） and venlanfaxine（n=63） for 12 weeks. HAMD, HAMA and NIHSS were used to as- sess the curative effect and adverse drug reactions were recorded before treatment and 6 and 12 weeks after treatment, respectively. RESULTS： After 12 weeks of treatment, HAMD, HAMA and NIHSS of 2 groups were significantly decreased, compared with be- fore treatment （P〈0.05）. The total effective rate of reboxetine group was 78.1% and that of venlanfaxine group was 79.4%, there was no statistical significance （P〉0.05）. No obvious adverse drug reactions were observed in 2 groups. CONCLUSION： In the treatment of post-stroke depression, reboxetine and venlanfaxine all have good curative effects, safety and compliance, and have light side effects.